



340B SUMMIT: THE BASICS AND BEYOND

PROGRAM AGENDA:

- | | |
|---------------|--|
| 8:30 – 8:45 | Welcome and Introduction of Speaker <ul style="list-style-type: none">• Gerrelda Davis, CEO Louisiana Primary Care Association |
| 8:45 – 9:30 | Opening Session <ul style="list-style-type: none">• Program Objectives and Review of Pre-conference Survey• One Health Center's 340B Journey |
| 9:30 – 10:15 | Part One: Program Framework <ul style="list-style-type: none">• Origin, purpose, and participants• Structure and federal oversight• How it works - pricing, savings, etc.• Implementation strategies for FQHCs (risks, benefits, and factors to consider for each)<ul style="list-style-type: none">○ In-house 340B pharmacy – with retail/without retail○ Contract pharmacy arrangements○ Clinic administered drugs and devices○ Combined strategies |
| 10:15 – 10:30 | BREAK |
| 10:30 – 11:45 | Part Two: Compliance Requirements <ul style="list-style-type: none">• Participation requirements:<ul style="list-style-type: none">○ Auditable records○ Registration and recertification• Prohibition against diversion<ul style="list-style-type: none">○ What is diversion?○ What makes a patient/prescription eligible?○ 340B eligibility across the continuum of care• Compliance with Medicaid<ul style="list-style-type: none">○ Prohibition against duplicate discount<ul style="list-style-type: none">▪ Duplicate discount defined▪ Role of the Medicaid Exclusion File: Carve-in/carve-out▪ The changing landscape with MCOs• Inventory management• Additional considerations re: contract pharmacy arrangements |

| | |
|---------------|---|
| 11:45 – 12:30 | LUNCH BREAK |
| 12:30 – 1:00 | Summary and follow-up questions from morning sessions |
| 1:00 – 1:45 | Part Three: Prepare to be Audited <ul style="list-style-type: none"> • HRSA Audits: Program Integrity Initiative <ul style="list-style-type: none"> ○ OPA audit history and findings to date ○ What to expect before, during and after the audit ○ 340B and Operational Site Visits ○ Prepare to perform well • Manufacturer audits <ul style="list-style-type: none"> ○ Why, what to expect, and how to respond? • Who else might come calling? |
| 1:45 – 2:30 | Part Four: Organizational Infrastructure <ul style="list-style-type: none"> • View from the C-Suite: Why and how the C-Suite should be involved • The role of the FQHC governing board • Recommended policy framework • Strategies for optimizing the value of 340B throughout the organization |
| 2:30 – 3:30 | Closing Session <ul style="list-style-type: none"> • Spotlight on 340B: Review of legislative and regulatory activity and current health policy climate as it relates to 340B • Challenges impacting 340B reimbursement: Covered Outpatient Drug Rule and beyond • How can we tell our story to support and protect the 340B Program? • Wrap-up, Q&A, and summary of questions and issues for follow-up |